Stock report · Delisted · Nasdaq
Plus Therapeutics Inc (PSTV)
3.84USD Delisted Final close · Aug 7, 2026
PSTV no longer trades. Plus Therapeutics was delisted from the Nasdaq in August 2026.
All prices on this page are historical. The last trade was on August 7, 2026, at $3.84.
PSTV stock price history
Final trading statistics
- Final close
- $3.84
- Final trading day
- Aug 7, 2026
- Market cap at delisting
- $26.42M
- Shares outstanding
- 6.88M
- Final 52-week range
- $0.13 – $8.00
- Avg. volume (final 3 mo.)
- 159,319
- All-time high
- $1000000.00 · Jul 2001
- All-time low
- $2.92 · Apr 2026
- Return since IPO
- -100.0%
- Beta
- 1.42
- Book value / share
- $1.74
- Price / book
- 2.20
About Plus Therapeutics Inc
Plus Therapeutics, Inc. was a clinical-stage drug company developing, making and selling cancer treatments. Its lead candidate, rhenium obisbemeda, was a patented radiotherapy for brain and other cancers, such as recurrent glioblastoma, leptomeningeal metastases and pediatric brain cancers.
It was also developing Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere, injected into arteries to treat solid organ cancers such as primary and secondary liver cancer. In addition, it offered lab-developed tests, including the CNSide Test, which finds tumor cells from carcinomas and melanomas that have spread to the central nervous system.
Founded in 1996 and based in Houston, Texas, the company was called Cytori Therapeutics, Inc. until July 2019. It was delisted from the Nasdaq in August 2026, with a final trade on August 7, 2026 at $3.84.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Houston, TX
- Employees
- 28
- IPO date
- November 16, 2000
- Delisted
- August 7, 2026
- SEC CIK
- 1095981
Plus Therapeutics financials before the delisting
The last 5 fiscal years Plus Therapeutics reported as a public company, fiscal year ending December.
PSTV revenue and net income
PSTV earnings per share
PSTV annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $5.21M | −$22.4M | −$15.37 |
| FY2024 | $5.82M | −$13.0M | −$39.74 |
| FY2023 | $4.91M | −$13.3M | −$93.09 |
| FY2022 | $224.0K | −$20.3M | −$232.72 |
| FY2021 | $0.00 | −$13.4M | −$322.54 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Plus Therapeutics stock FAQ
What happened to Plus Therapeutics stock?
Plus Therapeutics was delisted from the Nasdaq in August 2026. The final close was $3.84 on August 7, 2026.
Can I still buy PSTV stock?
No. PSTV is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on August 7, 2026.
What was the last price of PSTV?
PSTV last closed at $3.84 on August 7, 2026, which valued the company at about $26.42M.
How did Plus Therapeutics do in its last full fiscal year?
In fiscal 2025, its last full year as a public company, Plus Therapeutics reported revenue of $5.21M and net income of −$22.4M.
When did Plus Therapeutics go public?
Plus Therapeutics shares started trading on November 16, 2000.
PSTV no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.